SEATTLE--(BUSINESS WIRE)--
Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading immunotherapy company focused on developing treatments for cancer and autoimmune/inflammatory diseases, today announced the company will present a poster at the 2018 American Association for Cancer Research ("AACR") Annual Meeting taking place April 14 - 18, 2018 in Chicago, Illinois.
The poster, entitled “CD80 vIgD-Fc proteins combine checkpoint antagonism and costimulatory signaling for potent antitumor immunity,” will highlight preclinical data evaluating a novel immuno-oncology molecule derived from the company’s vIgD™ platform. An abstract of the presentation will be available on AACR website after March 14, 2018.
Presentation details are as follows:
|
Session Category: |
Clinical Research | |
|
Session Title: |
Immune Checkpoints 4 |
|
|
Session Date and Time: |
Tuesday, April 17, 2018 – 1:00 PM - 5:00 PM | |
|
Location: |
McCormick Place South, Exhibit Hall A, Poster Section 25 | |
|
Poster Board Number: |
5 |
A copy of the poster will be made available on the Company's website after it is presented.
About Alpine Immune Sciences, Inc.
Alpine Immune Sciences, Inc. is focused on developing novel protein-based immunotherapies using its proprietary variant Ig Domain (vIgD) platform technology. The vIgD platform is designed to interact with multiple targets including many present in the immune synapse. Alpine’s vIgDs are developed using a process known as directed evolution, which produces proteins capable of either enhancing or diminishing an immune response and thereby may potentially apply therapeutically to cancer, autoimmune, and inflammatory diseases. Alpine has also developed Transmembrane Immunomodulatory Protein (TIP) technology, based on the vIgD platform, to potentially enhance engineered cellular therapies. For more information, visit www.alpineimmunesciences.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20180314005269/en/
